Business Description
Syneos Health Inc
NAICS : 541714
SIC : 8731
ISIN : US87166B1026
Share Class Description:
FRA:8IN: Class ADescription
Syneos is a global contract research and outsourced commercialization organization that provides services to pharmaceutical and biotechnology firms. Its clinical solutions segment offers early- to late-stage clinical trial support that ranges from specialized staffing models to strategic partnerships that oversee nearly all aspects of a drug program, while the company's commercialization solutions includes outsourced sales, consulting, public relations, and advertising services.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.03 | |||||
| Equity-to-Asset | 0.43 | |||||
| Debt-to-Equity | 0.83 | |||||
| Debt-to-EBITDA | 6.26 | |||||
| Interest Coverage | 3.08 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 1.44 | |||||
| Beneish M-Score | -2.46 | |||||
| WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 7.1 | |||||
| 3-Year EBITDA Growth Rate | 13.1 | |||||
| 3-Year EPS without NRI Growth Rate | 29.4 | |||||
| 3-Year FCF Growth Rate | 11.7 | |||||
| 3-Year Book Growth Rate | 6.9 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 1.27 | |||||
| Future 3-5Y Total Revenue Growth Rate | 0.75 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 93.12 | |||||
| 9-Day RSI | 79.73 | |||||
| 14-Day RSI | 71.11 | |||||
| 6-1 Month Momentum % | 23.2 | |||||
| 12-1 Month Momentum % | -20.83 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.2 | |||||
| Quick Ratio | 1.2 | |||||
| Cash Ratio | 0.05 | |||||
| Days Sales Outstanding | 60.46 | |||||
| Days Payable | 10.7 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | 0.3 | |||||
| Shareholder Yield % | 0.72 |
Profitability Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 22.18 | |||||
| Operating Margin % | 6.4 | |||||
| Net Margin % | 1.43 | |||||
| FCF Margin % | 3.12 | |||||
| ROE % | 2.26 | |||||
| ROA % | 0.95 | |||||
| ROIC % | 4.03 | |||||
| ROC (Joel Greenblatt) % | 50.64 | |||||
| ROCE % | 3.15 | |||||
| Years of Profitability over Past 10-Year | 7 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 56.1 | |||||
| Forward PE Ratio | 11.51 | |||||
| PE Ratio without NRI | 56.1 | |||||
| Shiller PE Ratio | 40.36 | |||||
| Price-to-Owner-Earnings | 38.76 | |||||
| PEG Ratio | 2.24 | |||||
| PS Ratio | 0.8 | |||||
| PB Ratio | 1.29 | |||||
| Price-to-Free-Cash-Flow | 25.54 | |||||
| Price-to-Operating-Cash-Flow | 16.64 | |||||
| EV-to-EBIT | 35.5 | |||||
| EV-to-Forward-EBIT | 13.28 | |||||
| EV-to-EBITDA | 16.12 | |||||
| EV-to-Forward-EBITDA | 10.04 | |||||
| EV-to-Revenue | 1.33 | |||||
| EV-to-Forward-Revenue | 1.38 | |||||
| EV-to-FCF | 42.71 | |||||
| Price-to-Projected-FCF | 0.82 | |||||
| Price-to-DCF (Earnings Based) | 1.8 | |||||
| Price-to-DCF (FCF Based) | 0.82 | |||||
| Price-to-Peter-Lynch-Fair-Value | 4.5 | |||||
| Earnings Yield (Greenblatt) % | 2.82 | |||||
| FCF Yield % | 3.82 | |||||
| Forward Rate of Return (Yacktman) % | 18.98 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Syneos Health Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 5,161.442 | ||
| EPS (TTM) (€) | 0.713 | ||
| Beta | 0 | ||
| Volatility % | 47.76 | ||
| 14-Day RSI | 71.11 | ||
| 14-Day ATR (€) | 0.187152 | ||
| 20-Day SMA (€) | 39.38 | ||
| 12-1 Month Momentum % | -20.83 | ||
| 52-Week Range (€) | 25.665 - 51.08 | ||
| Shares Outstanding (Mil) | 103.72 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Syneos Health Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Syneos Health Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Syneos Health Inc Frequently Asked Questions
What is Syneos Health Inc(FRA:8IN)'s stock price today?
The current price of FRA:8IN is €40.00. The 52 week high of FRA:8IN is €51.08 and 52 week low is €25.67.
When is next earnings date of Syneos Health Inc(FRA:8IN)?
The next earnings date of Syneos Health Inc(FRA:8IN) is 2024-05-10 Est..
Does Syneos Health Inc(FRA:8IN) pay dividends? If so, how much?
Syneos Health Inc(FRA:8IN) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers